7.185
1.48%
0.095
Mannkind Corp stock is traded at $7.185, with a volume of 770.49K.
It is up +1.48% in the last 24 hours and up +10.86% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
See More
Previous Close:
$7.09
Open:
$7.02
24h Volume:
770.49K
Relative Volume:
0.33
Market Cap:
$1.98B
Revenue:
$248.37M
Net Income/Loss:
$11.74M
P/E Ratio:
-37.82
EPS:
-0.19
Net Cash Flow:
$18.24M
1W Performance:
+4.73%
1M Performance:
+10.86%
6M Performance:
+63.90%
1Y Performance:
+81.69%
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-10-23 | Initiated | Wedbush | Outperform |
May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
Dec-24-19 | Initiated | Oppenheimer | Outperform |
Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
May-14-19 | Initiated | BTIG Research | Buy |
Mar-04-19 | Initiated | SVB Leerink | Outperform |
Feb-22-19 | Initiated | SVB Leerink | Outperform |
Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
Oct-10-17 | Initiated | H.C. Wainwright | Buy |
Oct-06-17 | Reiterated | Maxim Group | Buy |
Aug-11-17 | Initiated | Maxim Group | Buy |
May-10-16 | Reiterated | Piper Jaffray | Underweight |
May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
May-11-15 | Reiterated | MLV & Co | Hold |
Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
MannKind (NASDAQ:MNKD) Reaches New 1-Year HighHere's What Happened - MarketBeat
MannKind Shares Soar to Over 8-Year Highs on United Therapeutics’ Tyvaso Revenue Surge: Retail Is Optimistic - MSN
MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease - ForexTV.com
MannKind (NASDAQ:MNKD) Sets New 1-Year HighTime to Buy? - MarketBeat
MannKind stock soars to 52-week high, touches $6.93 - Investing.com
MannKind Co. (NASDAQ:MNKD) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
MannKind Corporation Reports 2012 Fourth Quarter and Full Year Financial Results - AOL
SG Americas Securities LLC Takes Position in MannKind Co. (NASDAQ:MNKD) - MarketBeat
Mannkind Corp (MNKD) receives an Outperform rating from Leerink Partners - Knox Daily
Recent Insider Activity Could Benefit 3M Co. (MMM) - Knox Daily
Holdings of Mannkind Corp (MNKD) are aligned with the stars - SETE News
Selling Buzz: Mannkind Corp [MNKD] Chief People & Workpl Officer Tross Stuart A sells 25,000 shares of the company - Knox Daily
Ratios Revealed: Decoding Mannkind Corp (MNKD)’s Financial Health - The Dwinnex
MannKind Corp (MNKD) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Pipeline ... By GuruFocus - Investing.com Canada
MannKind Corp (MNKD) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Pipeline ... - Yahoo Finance
MannKind Corp (MNKD) Q2 2024 Earnings Call Highlights: Record Re - GuruFocus.com
Did Mannkind Corp (MNKD) perform well in the last session? - US Post News
Potential Price Increase for Mannkind Corp (MNKD) After Recent Insider Activity - Knox Daily
Mannkind Corp (MNKD) can make a big difference with a little luck - SETE News
Squarepoint Ops LLC Sells 133,926 Shares of MannKind Co. (NASDAQ:MNKD) - MarketBeat
Why MannKind (MNKD) Could Beat Earnings Estimates Again - Yahoo Finance
MannKind (MNKD) Just Overtook the 20-Day Moving Average - Yahoo Finance
MannKind Co. (NASDAQ:MNKD) Shares Purchased by Millennium Management LLC - MarketBeat
Exploring High Growth Tech Stocks In The United States October 2024 - Yahoo Finance
MannKind (NASDAQ:MNKD) Shares Up 3.2% - MarketBeat
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion - Seeking Alpha
Marshall Wace LLP Sells 205,764 Shares of MannKind Co. (NASDAQ:MNKD) - MarketBeat
A better buy-in window may exist right now for Mannkind Corp (MNKD) - SETE News
MannKind's SWOT analysis: inhaled therapeutics firm's stock shows promise amid challenges - Investing.com
More Adults With Type 1 Diabetes Achieved A1C Goal ( - Yahoo Finance
MannKind Co. (NASDAQ:MNKD) Shares Bought by Dark Forest Capital Management LP - MarketBeat
Mannkind Corp (MNKD)’s results reveal risk - US Post News
The Attractiveness of Investing In Mind Medicine Inc (MNMD) is Growing - Knox Daily
A new trading data show Mannkind Corp (MNKD) is showing positive returns. - SETE News
MNKD stock rated an Outperform by Leerink Partners - Knox Daily
Closing Figures: Mind Medicine Inc (MNMD)’s Negative Finish at 5.87, Down -1.68 - The Dwinnex
Manba Finance IPO Sees Stellar 73.18 Times Subscription on Second Day - Devdiscourse
Manba Finance IPO subscribed 73.18 times on Day 2 amid heavy demand from institutional investors - NewsDrum
Latest News - LatestLY
Mind Medicine Inc (MNMD) produces promising results - US Post News
Stock market update: Nifty Pharma index advances 0.23% - The Economic Times
Manba Finance IPO continues to attract great interest, subscribed 73 times on day 2 - Moneycontrol
Manba Finance IPO subscribed 56 times so far on Day 2 - Indiainfoline
Manba Finance IPO Day 2: Issue subscribed 41.11 times so far, check key dates and more - Upstox
Manaba Finance IPO Day 2: Check latest subscription, expected listing gains - India Today
Mankind Pharma To Raise Rs 7,000-Crore Debt For Bharat Serums Acquisition - NDTV Profit
Stock to buy today: Mankind Pharma (₹2,651.30): BUY - BusinessLine
Trade Spotlight: How should you trade Siemens, Mankind Pharma, Kotak Bank, DLF, Indegene and others on... - Moneycontrol
Avoro Capital Advisors LLC Reduces Stock Position in MannKind Co. (NASDAQ:MNKD) - MarketBeat
Manba Finance Limited IPO Subscribed 23.67 Times on Day 1 of Bidding, Sale To Conclude on September 25; - LatestLY
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):